GlassScriptPhysician profile
Ronald G Beebe
NPI 1760445852
$55,983.15
in general payments reported to CMS, 2019-2025
36 companies · $5,580 in 2025
The $5,580 reported for 2025 was more than what 84% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,480 · 2020: $5,154 · 2021: $22K · 2022: $6,647 · 2023: $2,505 · 2024: $13K · 2025: $5,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $6,172 · Education: $182 · Travel and Lodging: $163 · Consulting Fee: $45.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,050.00 |
| Food and Beverage | $6,172.27 |
| Education | $181.98 |
| Travel and Lodging | $162.74 |
| Consulting Fee | $45.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28,846.14 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $17,379.02 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,651.43 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,538.77 | 2020-2025 | Cuvitru, Takhzyro, Glassia |
| Csl Behring | $768.26 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Grifols USA, LLC | $675.54 | 2019-2025 | Xembify |
| Regeneron Healthcare Solutions, INC. | $610.03 | 2019-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $605.67 | 2021-2025 | Orladeyo |
| Mylan Specialty L.P. | $600.22 | 2019-2024 | Yupelri |
| Pfizer INC. | $575.89 | 2019-2025 | |
| Amgen INC. | $472.25 | 2021-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $301.74 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $297.41 | 2019-2025 | |
| Optinose US, INC. | $174.48 | 2021-2025 | |
| Octapharma USA, INC. | $172.08 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $156.98 | 2023-2025 | |
| Eyevance Pharmaceuticals LLC | $154.92 | 2021 | |
| Hikma Pharmaceuticals USA | $133.33 | 2022-2024 | Ryaltris |
| Pharming Healthcare, INC. | $112.83 | 2019-2025 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.62 | 2019-2021 | |
| Ionis Pharmaceuticals, INC. | $83.62 | 2025 | Dawnzera |
| Aimmune Therapeutics, INC. | $73.37 | 2022 | |
| Adma Biomanufacturing LLC | $60.56 | 2021-2024 | |
| Shire North American Group INC | $57.03 | 2019 | |
| Bio Products Laboratory USA, INC. | $53.43 | 2022 | |
| Cycle Pharmaceuticals INC | $49.15 | 2024-2025 | Sajazir |
| Abbvie INC. | $43.96 | 2023 | Rinvoq |
| Merck Sharp & Dohme LLC | $35.65 | 2021-2023 | |
| Alk-Abello, INC | $30.63 | 2022 | |
| Kaleo, INC. | $30.46 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $30.00 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $25.48 | 2025 | Nemluvio |
| Viatris Specialty LLC | $20.52 | 2025 | Yupelri |
| Verona Pharma, INC. | $20.03 | 2025 | Ohtuvayre |
| Phadia US INC. | $19.54 | 2022 | |
| Leo Pharma INC. | $17.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Beebe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.